Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Following disappointing clinical data for its lead asset, EO-3021, <a href="https://smartkarma.com/entities/elevation-oncology-inc">Elevation Oncology </a>has discontinued its development and is now exploring strategic alternatives to maximize shareholder value.</li>
 <li>The company has shifted its focus to its preclinical HER3-targeted antibody-drug conjugate (ADC), EO-1022, with plans to file an Investigational New Drug (IND) application in 2026.</li>
 <li>With a significant workforce reduction and a cash runway extended into the second half of 2026, the company is in a transitional period with high uncertainty, facing pressure from activist investors to wind down operations.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Following disappointing clinical data for its lead asset, EO-3021, Elevation Oncology has discontinued its development and is now exploring strategic alternatives to maximize shareholder value.
  The company has shifted its focus to its preclinical HER3-targeted antibody-drug conjugate (ADC), EO-1022, with plans to file an Investigational New Drug (IND) application in 2026.
  With a significant workforce reduction and a cash runway extended into the second half of 2026, the company is in a transitional period with high uncertainty, facing pressure from activist investors to wind down operations.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Elevation Oncology  (ELEV US) - Oct 2025

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing measles outbreak.</li><li>Flu vaccine guidelines for fall strains are not on the schedule, as the FDA issued recommendations without the usual ACIP guidance. </li><li>The CDC’s Division of HIV Prevention is under review, which could disrupt a major funding source of HIV prophylaxis (PrEP) drugs (GILD, GSK). </li></ul>

The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing measles outbreak.Flu vaccine guidelines for fall strains are not on the schedule, as the FDA issued recommendations without the usual ACIP guidance. The CDC’s Division of HIV Prevention is under review, which could disrupt a major funding source of HIV prophylaxis (PrEP) drugs (GILD, GSK). 

Biopharma Week in Review - March 24, 2025

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, ALDX completed the additional study needed to resubmit dry eye NDA.</li><li>Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, ALDX completed the additional study needed to resubmit dry eye NDA.Kidney disease drugs continue to benefit from regulatory tailwinds, as NVS gained IgAN approval and APLS succeeded in a pivotal biomarker study in C3G/IC- MPGN.

Biopharma Week in Review - August 12, 2024

United States

Elevation Oncology, Inc. operates as a biotechnology company. The Company focuses on the identification and targeted inhibition of tumor's specific drive alteration. Elevation Oncology serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Elevation Oncology (ELEV US)

Primer: Elevation Oncology (ELEV US) - Oct 2025

Following disappointing clinical data for its lead asset, EO-3021, Elevation Oncology has discontinued its development and is now exploring...

αSK

Biopharma Week in Review - March 24, 2025

The HHS rescheduled the CDC’s postponed February ACIP (vaccine experts panel) meeting for mid-April, with a revised agenda to include the ongoing...

Water Tower Research

Biopharma Week in Review - August 12, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)